On Thursday, Tempus AI, Inc. (NASDAQ:TEM) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform.
The update allows the generation of T1 and T2 inline maps, further enhancing the device’s cardiac MR image analysis capabilities.
